INS and Hypoglycemia: Another recent post hoc analysis examined whether Glar-300 could provide insulin-naïve patients on OADs with reductions in prior OAD therapy without compromising impact on HbA1c, while preserving the hypoglycemia benefit of Glar-300 versus Glar-100.